Genmab A/S passed its most significant milestone to date by obtaining its first drug approval, for ofatumumab (Arzerra) as a therapy for patients with chronic lymphocytic leukemia (CLL) who are refractory to fludarabine and alemtuzumab (Campath). (BioWorld International) Read More
